Studies of ex vivo activated and expanded CD8+ NK-T cells in humans and mice

Journal of Clinical Immunology

Volumn 22, Issue 3, 2002, Pages 131-136

  Verneris, Michael R ^a   Baker, Jeanette ^a   Edinger, Matthias ^a   Negrin, Robert S ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CD8+ NK T cells; CIK cells; GVHD; Immunotherapy

Indexed keywords

CD8 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 4;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; CONFERENCE PAPER; CYTOTOXICITY; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; HUMAN CELL; LYMPHOCYTE ACTIVATION; MOUSE; NATURAL KILLER CELL; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; ANIMAL; BLOOD DISEASE; CD8+ T LYMPHOCYTE; CULTURE TECHNIQUE; CYTOLOGY; IMMUNOLOGY; METHODOLOGY; REVIEW;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CELL CULTURE TECHNIQUES; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MICE;

EID: 0036267111     PISSN: 02719142     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1015415928521     Document Type: Conference Paper

References (40)

1. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation
2. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients
3. Donor leukocyte infusions in acute lymphocytic leukemia
4. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis
5. Human NK-cell receptors
6. NK cell receptors
7. Turning on natural killer cells
8. Suppression of graft-versus-host disease and amplification of graft-versus-tumor effects by activated natural killer cells after allogeneic bone marrow transplantation
9. Donor-type activated natural killer cells promote marrow engraftment and B cell development during allogeneic bone marrow transplantation
10. Ex vivo generation of human anti-pre-B leukemia-specific autologous cytolytic T cells
11. Regression of extensive pulmonary metastases in mice by adoptive transfer of antigen-specific cd8(+) ctl reactive against tumor cells expressing a naturally occurring rejection epitope
12. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients
13. Differential expression of CD8 alpha and CD8 beta associated with MHC-restricted and non-MHC-restricted cytolytic effector cells
14. A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency
15. Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells
16. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity
17. Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells
18. Sensitivity of multidrug-resistant tumor cell lines to immunologic effector cells
19. Expansion of cytotic CD3+CD56+ cells from peripheral blood progenitor cells of patients undergoing autologous hematopoietic cell transplantation
20. Expansion of Philadelphia chromosome-negative CD3(+)CD56(+) cytotoxic cells from chronic myeloid leukemia patients: In vitro and in vivo efficacy in severe combined immunodeficiency disease mice
21. Ewing's Sarcoma/PNET Tumor Cell Lines Express Her2/neu Which Can Be Utilized As A Target By Redirected T Cells
22. The Fas counterattack: A molecular mechanism of tumor immune privilege
23. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand
24. Resistance of ex vivo expanded CD3+CD56+ T cells to Fas-mediated apoptosis
25. Expansion of cytolytic CD8(+) natural killer T cells with limited capacity for graft-versus-host disease induction due to interferon gamma production
26. Tissue-specific segregation of CD1d-dependent and CD1d-independent NK T cells
27. CD1d-restricted and TCR-mediated activation of valpha 14 NKT cells by glycosylceramides
28. Mouse CD1-specific NK1 T cells: Development, specificity, and function
29. Heterogeneity of NK1.1+ T cells in the bone marrow: Divergence from the thymus
30. Engineering hematopoietic grafts: Purified allogeneic hematopoietic stem cells plus expanded CD8+ NK-T cells in the treatment of lymphoma
31. Ex vivo anti-CD3 antibody-activated donor T cells have a reduced ability to cause lethal murine graft-versus-host disease but retain their ability to facilitate alloengraftment
32. Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity
33. Memory CD8 T lymphocytes express inhibitory MHC-specific Ly 49 receptors
34. Recognition of the class Ib molecule Qa-1(b) by putative activating receptors CD94/NKG2C and CD94/NKG 2E on mouse natural killer cells
35. Ligands for the murine NKG2D receptor: Expression by tumor cells and activation of NK cells and macrophages
36. Fas and FasL in the homeostatic regulation of immune responses
37. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor
38. Induction of CD4+ T cell alloantigen-specific hyporesponsiveness by IL-10 and TGF-beta
39. Donor-derived interferon gamma is required for inhibition of acute graft-versus-host disease by interleukin 12
40. Autologous Cytokine-Induced Killer Cells For The Treatment of Relapsed Hodgkin's Disease and Non-Hodgkin's Lymphoma